Premium
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Author(s) -
Schade Sebastian,
Mollenhauer Brit,
Trenkwalder Claudia
Publication year - 2020
Publication title -
movement disorders clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 18
ISSN - 2330-1619
DOI - 10.1002/mdc3.12921
Subject(s) - entacapone , medicine , levodopa , pharmacology , adverse effect , observational study , drug , clinical trial , maximum tolerated dose , parkinson's disease , disease